Henry Schein, Inc. announced that its Board of Directors has authorized the repurchase of up to $750 million of the company's common stock. This new program is in addition to the $500 million repurchase program announced in January 2025, which is anticipated to be fully executed by the end of the first quarter of 2026.
As of September 8, 2025, Henry Schein had approximately 118.6 million shares outstanding, making this new authorization represent approximately 9.0% of shares outstanding at the current stock price. This decision reflects management's confidence in the 2025–2027 BOLD+1 Strategic Plan and its potential to deliver sustainable growth and value.
Separately, Henry Schein Medical expanded its SolutionsHub™ with the addition of Colaborate, a full-service management consulting firm for independent and hospital-based medical laboratories. This partnership aims to empower clinical laboratories across the U.S. to maintain compliance, enhance operational efficiency, and increase financial sustainability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.